Hormone replacement therapy – where are we now?

  title={Hormone replacement therapy – where are we now?},
  author={Robert D. Langer and Howard N. Hodis and Rogerio A. Lobo and Matthew A. Allison},
  pages={3 - 10}
Abstract Hormone replacement therapy (HRT) was the standard of care for menopause management until 2002, when perceptions changed following release of the initial results from the Women’s Health Initiative (WHI) trial. Fears of breast cancer and heart attacks engendered by that report were not supported by the data, especially for recently menopausal women. Clinically, HRT is usually initiated near menopause. The WHI tested something different – the effects of HRT started a decade or more after… 
4 Citations
Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma
Hormone replacement therapy does not appear to be detrimental to survival in cervical adenocarcinomas and there is a trend towards improved survival with hormone replacement therapy.
Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre
The longitudinal impact of the widely-publicised WHI 2002 study on women’s information-seeking and determinants of decision-making about managing menopausal symptoms are explored and reassurance to reach or justify decisions from a perceived trusted source can support informed decision- making is described.
The role of medications in successful aging
  • R. Langer
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2021
There is good evidence for MHT benefit in all-cause mortality and primary prevention of cardiovascular disease, diabetes and osteoporosis, and fair evidence for benefit in dementias, depression and osteoarthritis.
Current Resources for Evidence-Based Practice, July 2021.
  • Marit L. Bovbjerg
  • Medicine
    Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
  • 2021
How fetal monitoring may lead to overuse of birth-related interventions, commentaries on reviews focused on bedsharing, and women's lifetime estrogen exposure and risk of cardiovascular mortality are discussed.